Jennifer Spillane
Overview
Explore the profile of Jennifer Spillane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moniz Dionisio J, Ambrose P, Burke G, Farrugia M, Garcia-Reitboeck P, Hewamadduma C, et al.
J Neurol Neurosurg Psychiatry
. 2025 Jan;
PMID: 39798959
Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the...
2.
Lary C, Atkinson E, Spillane J, Nayema Z, Roy T, Peters R, et al.
J Bone Miner Res
. 2024 Dec;
40(2):231-240.
PMID: 39673185
Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial was performed at the Mayo Clinic which randomized postmenopausal women...
3.
Dodd K, Ahmed R, Ambrose P, Holt J, Jacob S, Leite M, et al.
Neuromuscul Disord
. 2024 Apr;
38:51-57.
PMID: 38626662
Azathioprine is recommended as the first-line steroid-sparing immunosuppressive agent for myasthenia gravis. Mycophenolate and methotrexate are often considered as second-line choices despite widespread consensus on their efficacy. We aimed to...
4.
Meisel A, Sacca F, Spillane J, Vissing J
Eur J Neurol
. 2024 Mar;
31(7):e16280.
PMID: 38523419
Background: Regular and consistent disease assessment could provide a clearer picture of burden in generalised myasthenia gravis (gMG) and improve patient care; however, the use of assessment tools in practice...
5.
Bharucha T, Brown R, Marcoci C, Benjamin L, Hoskote C, McNamara P, et al.
J Neurol Sci
. 2023 Oct;
453:120771.
PMID: 37793287
Background: Patients with suspected encephalitis continue to represent a diagnostic and therapeutic challenge, even in highly resourced centres. In February 2018, we set up a monthly in-person multidisciplinary team meeting...
6.
Franken D, Bouman K, Reumers S, Braun F, Spillane J, Pennings M, et al.
Neurology
. 2022 Oct;
99(20):e2223-e2233.
PMID: 36195450
Background And Objective: X-linked myotubular myopathy (XL-MTM) is an early-onset congenital myopathy characterized by mild to severe muscle weakness in male individuals. The objective was to characterize the clinical spectrum...
7.
Kapoor M, Hunt I, Spillane J, Bonnett L, Hutton E, McFadyen J, et al.
J Neurol Neurosurg Psychiatry
. 2022 Jun;
93(8):876-885.
PMID: 35688633
Background: Arterial and venous thromboembolic events (TEEs) have been associated with intravenous Ig use, but the risk has been poorly quantified. We aimed to calculate the risk of TEEs associated...
8.
Karunaratne K, Ahrabian D, Monoghan B, Campion T, Yousry T, Lunn M, et al.
BMJ Neurol Open
. 2021 Jun;
3(1):e000096.
PMID: 34079936
Background: Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic andcentral...
9.
Paterson R, Brown R, Vivekanandam V, Foulkes A, Thom M, Wiethoff S, et al.
Brain
. 2020 Dec;
143(12):e101.
PMID: 33324968
No abstract available.
10.
Lewis P, Plun-Favreau H, Rowley M, Spillane J
Mov Disord
. 2020 Oct;
35(10):1882.
PMID: 33068469
No abstract available.